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Background: In a previous study we demonstrated that, based on 11C/18 F-choline positron emission tomography-
computerized-tomography as a diagnostic tool, salvage lymph node dissection (LND) plus adjuvant radiotherapy
(ART) is feasible for treatment of pelvic/retroperitoneal nodal recurrence of prostate cancer (PCa). However, the
toxicity of this combined treatment strategy has not been systematically investigated before. The aim of the current
study was to evaluate the acute and late toxicity and quality of life of ART after LND in pelvic/retroperitoneal nodal
recurrent PCa.
Material and methods: 43 patients with nodal recurrent PCa were treated with 46 LND followed by ART (mean
49.6 Gy total dose) at the sites of nodal recurrence. Toxicity of ART was analysed by physically examination (31/43,
72.1%), by requesting 15 frequent items of adverse events from the Common-Terminology-Criteria for Adverse
Events Version 4.0-catalogue and by review of medical records. QLQ-C30 (EORTC quality of life assessment) and
PR25 (prostate cancer module) questionnaires were used to investigate quality of life. Toxicity was evaluated before
starting of ART, during ART (acute toxicity), after ART (mean 2.3 months) and at end of follow up (mean 3.2 years
after end of ART) reflecting late toxicity.
Results: 71.7% (33/46) of 46 ART were treatment of pelvic, 10.9% (5/46) of retroperitoneal only and 28.3% (13/46) of
pelvic and retroperitoneal regions. Overall 52 symptoms representing toxicities were observed before ART, 107
during ART, 88 after end of ART and 52 at latest follow up. Leading toxicities during ART were diarrhoea (19%,
20/107), urinary incontinence (16%, 17/107) and fatigue (16%, 17/107). The spectrum of late toxicities was almost
equal to those before beginning of ART. No grade 3 adverse events or chronic lymphedema at extremities were
observed. We observed no clear correlation between localisation of treated regions, technique of ART and
frequency or severity of toxicities. Mean quality of life at final evaluation was 74%.
Conclusion: ART after extended LND in PCa relapse is justifiable with respect to adverse effects and toxicity. The
side effects were circumscribed and well tolerated. The spectrum of adverse events at latest follow up was almost
equal to those before start of ART.
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Radical prostatectomy (RP) and radiotherapy (RT) are the
standard treatment options for clinically localized prostate
cancer (PCa) [1]. However relapses after primary treat-
ment of PCa occurs depended on initial tumor stages from
10 to 53% [2]. Different recurrence patterns exist: (1) evi-
dence of only local recurrence in the prostatectomy bed;
(2) evidence of loco-regional metastases in pelvic lymph
nodes (3) distant metastases (nodal, soft tissue, osseous)
and (4) a combination of local and distant metastases [3].
Salvage RT is the mainstay therapy in the setting of local
recurrence in the prostatic fossa and it offers the potential
of cure [4-6].
Magnetic Resonance Imaging (MRI) and Positron
Emmission Tomography/Computed Tomography (PET/
CT) using 18 F- or 11C-choline have the potential to
accurately identify the site of recurrence [5,7]. Choline-
PET/CT showed high region based sensitivity and speci-
ficity for detection of lymph node recurrence [8]. Nodal
recurrent PCa after primary treatment or after salvage
RT of the prostate fossa is considered an unfavourable
situation and androgen deprivation is administered as
standard therapy in this tumor stage. Antihormonal ther-
apy causes serious side effects and is of limited benefit due
to development of castration resistant PCa and therefore
serves merely as palliative therapy [9,10].
However there is increasing evidence that local ablative
therapy of LNM in the primary situation could reduce the
risk of progression [11] and it has been discussed, that
there may be a different outcome between patients with
solitary or few pelvic LNM compared to patients with
bone metastases [12].
Recently it has been reported that choline-PET/CT
guided salvage lymph node ablation therapy, either done
by surgery, surgery followed by adjuvant radiotherapy
(ART) or radiotherapy alone may be an effective strategy
with long term disease control and possible curative po-
tential [13-16]. Modern techniques such as image guided
ART enable the treatment of involved regions after
LND. This combination therapy is still investigational,
but appears reasonable while detection rates of a single
metastatic node by choline-PET/CT is limited by the
spatial resolution of 5 mm [8] and removal rates of sal-
vage surgery may be limited by altered lymphatic spread
due to prior surgical intervention [11].
There may be severe concern over anticipated side
effects of such a therapeutic approach. For example
lymphedema following treatment for gynecological cancer
has been reported to occur in up to 20% [17-19]. To our
knowledge there are no published data about combined
LND and ART of involved lymph node regions in patients
with nodal recurrence. Therefore the aim of the present
study was first to evaluate acute and late toxicity of this




43 patients with prostate specific antigen (PSA)-recur-
rence (PSA >0.2 ng/ml after radical prostatectomy, PSA
2 ng/ml above the nadir after primary radiotherapy in
2 consecutive measurements) and a choline-PET/CT
[11C-choline or 18 F-fluorethylcholine-PET/CT] positive
for lymph node metastases were treated with pelvic and/
or retroperitoneal salvage LND at Freiburg-University-
Hospital from 2005–2013. All PET/CT scans were
performed as a whole body imaging protocol with an
integrated multislice PET/CT scanner using intraven-
ous and oral contrast medium for enhanced CT to obtain
full diagnostic quality. A lesion was defined as focal tracer
accumulation greater than background activity with a cor-
responding lymph node in pelvic or retroperitoneal regions
in the coregistrated CT.
Inclusion criteria were verification of biochemical recur-
rence, presence of choline-PET/CT positive lymph node
metastases (regardless of number) without detectable bone
or visceral metastases, Charlson-Comorbidity-index ≤2,
age <80 years. Antihormonal therapy, if administered
beforehand, had to be discontinued for at least 8 weeks.
All patients underwent additional bone-scintigraphy to
confirm exclusion of skeletal metastases. 46 ART were
performed. 3 patients had 2 salvage lymph node dissec-
tions and 2 ART at different sites. Because of the experi-
mental character of the surgical intervention (salvage
lymph node dissection) and the adjuvant radiotherapy
the patients had to sign informed consent. Furthermore,
the patients gave signed written consent with respect to
this retrospective analysis. The local review board reviewed
and approved the study (No. 135/12_130160).
Salvage lymph node dissection
According to choline-PET/CT findings pelvic (10 subre-
gions: common iliac vessels, external iliac vessels, obtura-
toria vessels, internal iliac vessels, presacral region) or/and
retroperitoneal (4 subregions: aortic bifurcation, aortal,
caval, interaortocaval) LND was performed. Salvage-LND
included complete removal of lymphatic and fatty tissue.
The genitofemoral nerve formed the lateral border for
pelvic lymphadenectomy. All LNDs were performed by
the same surgeon (WSS).
Adjuvant radiotherapy
Pelvic and retroperitoneal great vessels served as guid-
ance to define clinical target volume (CTV). The cranial
border of the retroperitoneal LN-region were the renal
vessels, the inferior border the aortic bifurcation. The
cranial border of a pelvic region (left/right) was the
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port were the top of the femoral heads. An approximately
8–10 mm margin around the vessels was drawn to define
the CTV. Planning target volume (PTV) was 5–7 mm
around the CTV. The following dose restrictions to re-
duce normal tissue complication probability were used
as guidelines in radiotherapy planning: small bowel V45
Gy <250 ml, V50 Gy < 100 ml; rectum V50 Gy <50%,
bladder V55 Gy < 50% [20,21]. LN-regions were treated
five times a week with 1.8 Gy/fraction up to a mean
dose of 49.6 Gy (median 50.4 Gy, SD: 4.16 Gy, range
45–59.4 Gy) with 3D conformal irradiation or Intensity
Modulated Radiation Therapy (IMRT). Due to dose
constraints in adjacent normal tissues (small bowel,
colon) shrinking field technique in terms of dose escal-
ation >45 Gy to involved LN-regions was performed in
11/46 cases. If imaging suggested presence of local recur-
rence (12/43 patients), based on MRI and choline-PET/
CT findings, prostate fossa received dose escalation (mean
69.2 Gy). Volumes of prior irradiation were excluded.
Linear accelerators with 6 and 10 MV photons were
used equipped with electronic portal imaging.
Sources for evaluation of toxicity
To retrospectively evaluate the toxicity of ART, 31/43 pa-
tients were physically consulted in the out-patient-facility
of the Departments of Urology or Radiation Oncology. A
catalogue containing 15 selected items of possible adverse
events/side effects (constipation, diarrhoea, rectal bleed-
ing, nausea/vomiting, haematuria, urinary incontinence,
dysuria (including: urgency, feeling of obstruction, pain),
skin erythema in radiated region, skin hyperpigmentation
in radiated region, lymphedema lower extremity, lympho-
cele, paraesthesia, fatigue/exhaustion, thrombosis, embol-
ism) was extracted from the CTCAE-classification-list
[22] and applied for every patient resp. every performed
ART. Side effects were related to different time points (be-
fore ART, during ART, after ART and at latest follow up).
Physical examination of the patients (abdomen, skin, lower
extremity) and a comprehensive review of the medical re-
cords from the Departments of Urology and Radiation
Oncology completed the assessment. 31/43 (72%) patients
had been physically examined and consulted. 5/43 (11.5%)
patients were out of the question of being invited due to
death during follow up. Those 5 patients died because of
progressive PCa, time from end of ART to death was 1.5,
3.5, 3.8, 5.9 and 2.7 years. 5/43 (11.5%) were missed be-
cause of extraordinary long journey from residence to
Freiburg Hospital and 2/43 (5%) refused the invitation for
an extra examination at latest follow up.
EORTC questionnaires
Both, QLQ-C30 and PR25 questionnaires were devel-
oped by the European Organization for Research andTreatment of Cancer (EORTC) Quality of Life Study
Group [23,24]. The QLQ-C30 contains 30 items (phys-
ical, role, emotional, cognitive and social function and
global health status). Furthermore, several specific phys-
ical symptoms such as fatigue, nausea/vomiting, pain,
dyspnoea, sleep disturbance, loss of appetite, constipa-
tion, diarrhoea and financial difficulties are covered.
Each item is scored from 1 to 4 (1 = “not at all”, 2 = “a
little”, 3 = “quite a bit”, 4 = “very much”). Global quality
is scored from 1 (very poor) to 7 (excellent). The PR25
questionnaire is a prostate specific module to be used in
combination with the QLQ-C30 questionnaire and con-
tains 25 items (urinary symptoms – 9 items, bowel
symptoms – 4 items, treatment related symptoms – 6
items, sexual function – 6 items). A high score for a
functional scale represents a high, healthy level of func-
tioning; a high score for the global health status QoL
represents a high quality of life. A high score for a
symptom scale item represents a high level of symptom-
atology. Questionnaire data were processed according
to the EORTC QLQ-C30 scoring manual [25].
Data from prostate cancer module PR25 were pre-
ceded according to the recommendations of the EORTC
Quality of Life Study Group. Missing items were treated
according to the recommendations given in the manual:
if at least half of the items from the scale had been an-
swered, it was assumed that the missing items had
values equal to the average of those items which were
present for that respondent [24].
Statistical analysis
Descriptive statistic was done by calculating means, me-
dians and standard deviations. Continuous variables were
compared with a two-sided unpaired t-test. Chi-square-
test was used for analyzing contingency tables. Signifi-
cance was assumed if p < 0.05. Cronbach’s coefficient α
was calculated to analyse the internal consistency of the
scales from the questionnaires. All statistics were done
with SPSSv19 (IBM Corp. Armonk, NY, USA).
Results
Patient characteristics with respect to initial PCa stage
and primary therapies from 43 individuals are shown in
Table 1. Table 2 presents results from 46 LND performed
in 43 patients because of nodal PCa relapse after primary
therapy. All 43 patients underwent choline-PET/CT-
imaging before lymphadenectomy. ART after LND was
performed in 46 cases. Data from 46 ARTs with respect
to region, total dose, the performance of a boost in af-
fected regions and concurrent radiation of prostatic fossa
are given in Table 3.
Figure 1 shows a representative choline-PET/CT from
a patient with positive lymph nodes in the right obtur-
ator region in 09/12, the second lymph node was located
Table 1 Patient characteristics regarding initial prostate
cancer stage and primary therapy from 43 patients
Variables Value
Primary therapy
Radical prostatectomy n (%) 38/43 (88.4%)
Radiotherapy n (%) 5/43 (11.6%)
Age at primary therapy (years)
Mean/SD/median/range 60.3/6.1/60.0/74 - 46




















Initial PSA at primary therapy (ng/ml)
Mean/SD/median/range 16.4/14.83/10.9/4.2 – 24.96
Salvage-LND = Salvage lymph node dissection; SD = Standard deviation.
PSA = Prostate specific antigen (ng/ml).
Table 2 Data from 46 salvage lymph node dissections
from 43 patients with nodal prostate cancer relapse
Variables Value
Age at salvage lymph node dissection (years)
Mean/SD/median/range 64.9/5.9/65.2/75 - 53
Time from primary therapy to salvage lymph
node dissection (years)
Mean/SD/median/range 4.9/3.4/4.4/15.7 – 0.4
Regions affected with lymph node metastases
(Histopathology) n (%)
Pelvic only 31/46 (67%)
Retroperitoneal only 5/46 (11%)
Pelvic and retroperitoneal 9/46 (20%)
Retroclavicular and retroperitoneal 1/46 (2%)
Number of lymph nodes removed per surgery
Mean/SD/median/range 29.3/14.6/29.5/2 - 62
Number of removed lymph nodes metastases
per surgery
Mean/SD/median/range 7.9/4.5/8.6/1 - 44
PSA at salvage lymph node dissection (ng/ml)
Mean/SD/median/range 8.7/14.5/3.2/0.57 – 72.62
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choline-PET/CT of the same patient in 10/13 after LND
and ART of the pelvic lymph node regions. There was
no evidence for pelvic lymph node recurrence. The
IMRT-Boost plan influenced by choline-PET/CT find-
ings is shown in Figure 3. This patient received local
boost irradiation up to a sum dose 56,6 Gy.
Time from end of ART to first follow-up visit was
mean 2.3 months (median 1.95 months, SD: 1.19 months,
range: 6.23 – 0.9 months). Time from end of ART to lat-
est follow up was mean 3.2 years (median 2.7 years, SD:
2.89 years, range: 10.1 -0.2 years).
Distribution of overall toxicities, regardless of the
CTCAE-grading, before ART, during ART, after ART and
at latest follow up, are shown in Figure 4A-D. Toxicity
during ART (Figure 4B) and toxicity after ART (first
follow up visit, Figure 4C) reflect the acute side effects
and the therapy related symptoms at latest follow upreflect late toxicity. Before beginning of ART 52 ther-
apy related ‘baseline’ symptoms were recorded resp.
107 symptoms during ART, and 88 after end of ART
(first follow up visit), 52 therapy related symptoms were
recorded at latest follow up (Figure 4A-D). Proportion
of patients affected from one symptom of 15 recorded
items at the different time points are shown in Table 4.
Only with respect to urinary incontinence, diarrhoea,
skin erythema and development of lymphoceles grade 2
toxicities had been observed in our study. Grade 2 urinary
incontinence during ART was observed in overall 9 cases,
3 of those 9 adverse events occurred upon pelvic and
retroperitoneal ART, 5/9 events occurred upon pelvic only
ART, one case of urinary incontinence was associated with
retroperitoneal only ART. 5 cases with grade 2 diarrhoeas
were observed. 3 of those 5 occurred from ART of pelvic
and retroperitoneal lymph node regions, 2/5 grade 2 di-
arrhoeas occurred from pelvic only ART. 6/9 patients
who complained about grade 2 urinary incontinence
had been treated with 3D-conformal radiation tech-
nique; the remaining 3/9 individuals had been treated
using IMRT. 4/5 patients with grade 2 diarrhoea were
treated with 3D-ART, the remaining individual was
treated with IMRT.
By evaluating 15 symptoms/items (Table 4) during
radiotherapy from 17 IMRTs and 29 3D-ARTs, the
overall rate of toxicity, regardless of the grading, was
compared between both techniques. In the IMRT-
group 44 of 255 possible toxicities were observed, 63 of
435 possible toxicities were recorded in the 3D-ART
Table 3 Data from 46 adjuvant radiotherapies from 43
patients
Variables Value
Age at adjuvant radiotherapy (years)
Mean/SD/median/range 64.8/5.81/65.3/75 - 54
Time from salvage lymph node dissection
to adjuvant RT (months)
Mean/SD/median/range 2.75/1.72/2.20/8.4 - 0.8
Region for adjuvant RT n (%)
Pelvic right only 2/46 (4.3%)
Pelvic left only 5/46 (10.9%)
Pelvic only (left/right/bilateral) 26/46 (57%)
Retroperitoneal only 5/46 (11%)
Pelvic and retroperitoneal 14/46 (30%)
Retroclavicular and retroperitoneal 1/46 (2%)
Cases with dose escalation on involved
region n (%)
11/46 (24.0%)
Method of adjuvant radiotherapy
3D-conformal radiotherapy n (%) 29/46 (63%)
IMRT n (%) 17/46 (37.0%)
Concurrent radiation of prostatic fossa
n (%)
12/46 (26.1%)
Total dose for radiation of prostatic
fossa (Gy)
Mean/SD/median/range 69.18/2.38/70.20/45.0 – 72.2
Duration of adjuvant radiotherapy
(months)
Mean/SD/median/range 1.39/0.35/1.37/2.4 – 1.0
Dose per fraction (Gy) 1.8, 5x1.8/week
Total dose for pelvic or retroperitoneal
RT (Gy)
Mean/SD/median/range 49.55/4.16/50.40/45.0 – 59.4
Number of cases with concurrent AHT
at radiotherapy n (%)
2/46 (4.3%)
Patients with concurrent AHT at latest
follow up
27/43 (62.8%)
Comorbidities at latest follow1 up n (%)
Cardiovascular disease n (%) 10/38 (26.4%)
Diabetes mellitus n (%) 3/38 (7.9%)
Concurrent malignant disease n (%) 3/38 (7.9%)
Chronic disease/chronic pain n (%) 6/38 (15.9%)
RT = Radiotherapy.
AHT = Antihormonal therapy.
IMRT = Intensity-modulated radiation therapy.
1Mean 3.2 (SD: 2.8) years after end of radiotherapy.
Figure 2 Choline-PET/CT of the same patient as in Figure 1 in
10/13. After salvage lymph node dissection and adjuvant radiation
of the pelvic regions, there was no evidence for pelvic lymph
node recurrence.
Figure 1 Patient with two choline-PET/CT positive lymph nodes
in the right obturator region in 09/12. The second lymph node
metastases was located at the iliaca communis subregion.
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both groups (p-value: 0.33).
Diarrhoea and urinary incontinence were the leading
symptoms during ART (Figure 4B and Table 4). 8 events
of diarrhoea during ART were recorded upon 14 pelvic
and retroperitoneal treatments resp. 12 cases of diarrhoeaoccurred upon 26 ARTs of the pelvis only. With respect to
the extent of the irradiated regions the frequency of diar-
rhoea (regardless of grading) was not significant different
between both groups (p-value: 0.74).
Upon 26 pelvic ARTs, 8 events of urinary incontinence
during ART were recorded. Upon 14 pelvic and retro-
peritoneal ARTs 4 cases of urinary incontinence were
noticed. No significant difference was observed between
both conditions (p-value: 0.33).
Generally the fraction of patients with urinary incon-
tinence before start of ART (14/46) was not significant
different (p-value: 0.494) from the fraction of patients
with incontinence at latest follow up (14/37). Also the
Figure 3 Same patient as in Figures 1 and 2. Picture shows an example of the IMRT-Boost-plan that was influence by the choline-PET/CT-findings.
This patient received local boost irradiation up to a sum dose 56,6 Gy.
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(4/46) was not significant different (p-value: 1.0) from
the fraction of patients who had diarrhoea at latest
follow up (4/37).
5 events with paraesthesia during ART were recorded
(Table 4). 4/5 paraesthesias had already been noticed be-
fore ART (1/5 general polyneuropathy, 1/5 right inguinal,
1/5 inner region thigh, 1/5 inguinal right). No progression
during or after ART was observed. Only one patient (1/5)
complained about newly diagnosed paraesthesia (inguinal
left and right and thigh right) that had not existed before
ART.
2 patients had residual lymphoceles from salvage LND,
without indication for drainage because of small size and
lacking symptoms (Table 4). One patient developed a
pelvic lymphocele during ART with indication for drain-
age, clearly related to performed salvage lymphadenec-
tomy recently before.6 patients showed lymphedema (grade 1) during ART.
5/6 of those had lymphedemas already before beginning
of ART (2/6 swelling upper and lower leg right post sal-
vage LND, 1/6 ankle oedema, 1/6 lower leg oedema left,
1/6 upper leg oedema with varicosis). 1 patient devel-
oped newly grade 1 lymphedema at the right upper leg
region.
Hematopoetic parameters (level of haemoglobin, leuko-
cytes, thrombocytes) at different time points are shown in
Table 5. A significant difference before and during ART
was observed only for the level of leucocytes (6,600/μl
versus 4,800/μl, p-value 0.0009, CI: 2.75 - 0.75).
At latest follow up 21/43 of the patients (46%) were
ECOG 0 status, 14/43 (30%) were ECOG 1 status (not
evaluable 24% (11/43)).
Results of EORTC quality of life (QLQ-C30) and
EORTC prostate cancer module (QLQ-PR25) from 36 pa-









Dysuria (urgency, feeling of obstruction, pain) 8%
Fatigue / exhaustion 19%
Diarrhea 19%
Urinary incontinence 16%
Fatigue / exhaustion 16%







Skin erythema in radiated region 12%





Dysuria (urgency, feeling of obstruction, pain) 6%
Lymphedema extremity 7%
Constipation 7% 
Skin erythema in radiated region 10%
Diarrhea 12%
Fatigue / exhaustion 18%
Urinary incontinence 18%
Skin hyperpigmentation in radiated region 7%
Urinary incontinence 27%





Dysuria (urgency, feeling of obstruction, pain) 8%
Skin hyperpigmentation in radiated region 6%
Rectal bleeding 2%
Haematuria 2%













n = 52 overall registrated 
toxicities
n = 107  overall registrated 
toxicities
n = 88  overall registrated 
toxicities
n = 52  overall registrated 
toxicities
* mean 2.3 months, median 1.95 months, SD 1.49 months
** mean 3.2 years, median 2.7 years, SD 2.89 years
Figure 4 Distribution (n, %) of overall recorded toxicities at different time points: A) before, B) during, C) after and D) at latest follow
up from 46 radiotherapies. The coloured panels reflect the percentage distribution of adverse events at different time points regardless of
the CTCAE-grading.
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Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 6/46 (13.0%) 6/6 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Diarrhea
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 20/46 (43.5%) 15/20 (75.0%) grade 1/5/20 (25.0%) grade 2
After ART1 11/46 (23.9%) 11/11 (100%) grade 1
Latest follow up2 4/37 (10.8%) 4/4 (100%) grade 1
Rectal bleeding
Before ART 3/46 (6.5%) 3/3 (100%) grade 1
During ART 2/46 (4.3%) 2/2 (100%) grade 1
After ART1 2/46 (4.3%) 2/2 (100%) grade 1
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Nausea/Vomiting
Before ART 0/46 (0.0%) -
During ART 4/46 (8.7%) 4/4 (100%) grade 1
After ART1 0/46 (0.0%) -
Latest follow up2 0/37 (0.0%) -
Haematuria
Before ART 2/46 (4.3%) 2/2 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 4/46 (8.7%) 4/4 (100%) grade 1
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Urinary incontinence
Before ART 14/46 (30.4%) 12/14 (85.7%) grade 1/2/14 (14.3%) grade 2
During ART 17/46 (36.9%) 8/17 (47.1%) grade 1/9/17 (52.9%) grade 2
After ART1 16/46 (34.7%) 9/16 (56.3%) grade 1/7/16 (43.7%) grade 2
Latest follow up2 14/37 (37.8%) 10/14 (71.4%) grade 1/4/14 (28.6%) grade 2
Dysuria (urgency, feeling of obstruction, pain)
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 7/46 (15.2%) 7/7 (100%) grade 1
After ART1 5/46 (10.9%) 5/5 (100%) grade 1
Latest follow up2 4/37 (10.8%) 4/4 (100%) grade 1
Skin Erythema in radiated region
Before ART 0/46 (0.0.%) -
During ART 13/46 (28.3%) 13/13 (100%) grade 1
After ART1 9/46 (19.6%) 6/9 (66.7%) grade 1/3/9 (33.3%) grade 2
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Skin hyperpigmentation in radiated region
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
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Table 4 Evaluation of frequent side effect before/during/after ART and at timepoint of evaluation in 43 patients from
46 adjuvant radiotherapies (Continued)
After ART1 6/46 (13.0%) 6/6 (100%) grad 1
Latest follow up2 3/37 (8.1%) 3/3 (100%) grade 1
Lymphedema extremity
Before ART 5/46 (10.9%) 5/5 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 6/46 (13.0%) 6/6 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Lymphocele
Before ART 2/46 (4.3%) 2/2 (100%) grade 1
During ART 3/46 (6.5%) 2/3 (66.7%) grade1/1/3 (33.3%) grade 2
After ART1 2/46 (4.3%) 2/2 (100%) grade 1
Latest follow up2 0/37 (0.0.%) -
Paresthesia
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 5/46 (10.9%) 5/5 (100%) grade 1
After ART1 5/46 (10.9%) 5/5 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Fatigue/exhaustion
Before ART 10/46 (21.7%) 10/10 (100%)
During ART 17/46 (37.0%) 17/17 (100%)
After ART1 16/46 (34.8%) 16/16 (100%)
Latest follow up2 9/37 (24.3%) 9/9 (100%)
Thrombosis
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
After ART1 0/46 (0.0.%) -
Latest follow up2 0/37 (0.0.%) -
Embolism
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
After ART1 0/46 (0.0.%) -
Latest follow up2 0/37 (0.0.%) -
ART = adjuvant radiotherapy.
1Mean 2.3 (SD: 1.2) months after end of radiotherapy.
2Mean 3.2 (SD: 2.8) years after end of radiotherapy.
3Common Terminology Criteria for Adverse Events Version 4.0.
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Calculated Cronbach’s alpha for PRURI-score, PRBOW-
score, PRHTR-score, PRSAC-score and PRSFU-score was
0.82, 0.34, 0.50, 0.64 and 0.53 respectively. Calculated
Cronbach’s alpha for PF2-score, RF2-score, EF2-score,
CF-score, SF-score, FA-score, NV-score, PA-score and
QL2-score was 0.64, 0.91, 0.90, 0.74, 0.81, 0.84, 0.73,
0.76 and 0.88 respectively. These data indicate a good to
excellent internal consistency in most of the checked
items.Discussion
The results of this study showed that salvage ART after
extended LND in prostate cancer relapse has acceptable
low acute and late toxicity resulting in a high quality of
life at mean 3.2 years afterwards. 88.4% of all patients
had lymphadenectomy at primary therapy when radical
prostatectomy and lymphadenectomy was performed
(Table 1). However the second salvage lymphadenec-
tomy was performed as an extended surgery represented
by the mean number of 29.3 lymph nodes (Table 2).
Table 5 Hematopoetic parameters before, during and
after adjuvant radiotherapy in 46 cases from 43 patients
Hemoglobin Gram/dl
Before ART1 13.8/1.79/14.0 (mean/± SD/median)
During ART2 13.01/1.37/13.0 (mean/± SD/median)





Before ART1 6.58/2.07/6.30 (mean/± SD/median)
During ART2 4.81/1.53/4.40 (mean/± SD/median)





Before ART1 240.43/74.84/226.50 (mean/± SD/median)
During ART2 204.17/71.84/192.0 (mean/± SD/median)




ART = adjuvant radiotherapy.
1Mean 2.4 months before start of ART (SD: 2.5 months, median 1.78 months).
2Mean 0.80 months after start of ART (SD: 0.46 months, median 0.70 months).
3Mean 2.9 months after end of ART (SD: 3.15 months, median 1.57).
Table 6 EORTC quality of life questionnaire (QLQ-C30) at
timepoint of evaluation [Mean 3.2 (SD: 2.8) years after
end of radiotherapy]
QLQ-C30 functional scores Value (mean/± SD/median)
Physical functioning (PF2 –score) 87.1/14.9/93.3
Role functioning (RF2-score) 87.3/21.3/100.0
Emotional functioning (EF-score) 76.5/24.6/91.7
Cognitive functioning (CF-score) 82.8/27.2/100.0
Social functioning (SF-score) 77.0/26.6/83.3






Appetite loss (AP-score) 3.9/10.9/0.0
Constipation (CP-score) 8.8/20.9/0.0
Diarrhea (DI-score) 14.7/22.0/0.0
Financial difficulties (FI-score) 9.8/25.3/0.0
Quality of life Value (mean/± SD/median)
QoL-score 74.0/19.7 / 83.3
Table 7 EORTC prostate cancer module (QLQ-PR25) at
timepoint of evaluation [Mean 3.2 (SD: 2.8) years after
end of radiotherapy]
PR25 functional scores Value (mean/± SD/median)
Sexual activity (PRSAC-score) 36.8/29.4/33.3
Sexual functioning (PRSFU-score) 47.2/25.4/33.3
PR25 Symptom scores Value (mean/± SD/median)
Urinary symptoms (PRURI-score) 24.9/20.8/19.5




Incontinence aid (PRAID-score) 24.6/32.2/0.0
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edema may be considered fairly high due to at least
threefold treated and possibly altered pelvic or retroperi-
toneal lymph node regions but in fact was not. Similarly
in contrast to reported toxicities of adjuvant irradiation
in gynaecological cancer a recent published series of pa-
tients that underwent pelvic irradiation after extended
pelvic lymphadenectomy because of node-positive PCa
in the primary situation showed low incidence of lymph-
edema with only mild characteristic [26]. In this series
26 patients underwent combined treatment for high-risk
node-positive prostate cancer consisting of extended pel-
vic lymphadenectomy followed by androgen deprivation
therapy and radiotherapy of pelvic lymph nodes, prostate
including seminal vesicles with external beam radiother-
apy (50 Gy) followed by brachytherapy boost of 2×10 Gy
to the prostate only. With a median follow up of 2.2 years
six patients (27%) experienced grade 1 lymphedema and
two patients (9%) grade 2 while none had grade 3 or 4 ac-
cording to the CTC Common Toxicity Criteria scale 4.0
including only mild urinary and rectal side effects [26].
Another series of 39 patients that received adjuvant pelvic
IMRT because of node-positive prostate cancer in the
primary situation has been published by Müller et al.
[27]. Pelvic IMRT to 45–50.4 Gy was applied either after
previous surgery including lymphadenectomy (n = 18) or
with a radiation boost to suspicious nodes (n = 21) with
doses of 60–70 Gy. They reported no lymphedema and
only moderate acute radiation-related genitourinary and
gastrointestinal toxicity (Grade 1–2), while 2 patients had
potential severe toxicities of G3-4 (with the need for urin-
ary catheter/subileus related to adhesions after surgery).
Late toxicity was mild (Grade 1–2) after a median follow
up of 70 months/5.8 years and over 50% of the patients
reported no late morbidity. In their study in the group
with lymphadenectomy a mean of 13 nodes had been
removed. These and our studies are in contrast to data
from gynaecologic studies that investigated toxicity after
surgery and adjuvant radiation in cervical cancer: Land-





























































































































Figure 5 Mean functional and symptoms scales and quality of life-score from the QLQ-C30 questionnaires. Mean functional scales (A),
symptoms scales (B) and (C) quality of life-score from the QLQ-C30 questionnaires analysed from (31/43, 72.1%) patients evaluated mean 3.2 years
after end of radiotherapy.
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retrospective study on the prevalence of lymphedema
after gynecological cancer treatment (n = 802) showed
prevalence of lymphedema in 10% and presence of

























































Figure 6 Mean functional and symptoms scales from the prostate can
(A) and symptoms scales (B) from the prostate cancer module QLQ-PR25 q
3.2 years after end of radiotherapy.diagnosed lymphedema was more prevalent (36%) amongst
vulvar cancer survivors and cervical cancer survivors who
had radiotherapy or lymph node dissection had higher
odds of developing swelling [17]. A retrospective study on
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showed that 36% of the women reported swelling of their
legs with clincically diagnosed lymphedema in 18% [19].
Patients were most likely to develop lymphedema if they
underwent adjuvant radiotherapy after dissection of lymph
nodes in the groin region. No groin lymph node dissection
was performed in our series, because the typically involved
lymph nodes in prostate cancer patients with nodal recur-
rence are the proximal iliaca external, internal and iliaca
communis subregions [8]. Additionally we investigated the
possible effect of IMRT vs. 3D conformal radiation tech-
nique on the prevalence of side effects, but there was no
significant difference between both techniques. Only 24%
received dose escalation of the involved lymph node sub-
region, while in these cases the total dose did not exceed
59.4 Gy. The reason for dose escalation was the presence
of histological confirmed extensive lymphatic spread in
a lymph node subregion with a higher risk of residual
disease despite salvage lymph node dissection. However
also in such situations normal tissue dose restrictions as
mentioned in the methods section were strictly followed,
explaining the low toxicities. Mild Diarrhoea and mild
urinary incontinence were frequent in the spectrum of
toxicities. Both are typical acute side effects of pelvic/
retroperitoneal irradiation [26,27]. However long term
toxicity was lower than acute side effects and the
spectrum of late toxicity matched the spectrum before
adjuvant radiotherapy indicating nearly complete heal-
ing up of side effects (Figure 4). Fatigue was the second
most symptom before and after ART but did not in-
creased at latest follow up. Our data showed are consid-
erably lower prevalence and severity of long term side
effects than a recent study on the effects of pelvic radio-
therapy on cancer survivors including men and women
(n = 418) [29]. Adams et al. described a higher incidence
of moderate (grade 2) and severe (grade 3/4 problems
with bowel, urinary and sexual functioning: bowel urgency
(59% women, 45% men); urine urgency (49% women, 46%
men); urine incontinence (38% women, 9% men). Study
symptoms were just as frequent in those 6–11 years after
treatment as in those 1–5 years after treatment. Symptom
severity was significantly associated with poorer overall
quality of life and higher levels of depression. The authors
concluded that late effects are common among long-term
cancer survivors who have had pelvic radiotherapy, and
are associated with reduced quality of life. In contrast
quality of life functional and symptom scores and global
health status were somewhat similar to our results (mean
72% [29] vs. mean 74% (Table 6)). The higher gastrointes-
tinal and urinary toxicity in their study compared to our
data is on the one hand likely due to the inclusion of men
with bladder and rectal cancer beside patients with pros-
tate cancer, each entity requiring different target volumes.
On the other hand no detailed information aboutradiotherapy and surgery has been reported in their study.
In addition it is unclear which dose restrictions and vol-
umes of irradiation have been used in their population.
These considerations are likely to explain the difference to
the mild grade of toxicity in our cohort.
A significant proportion of the patients reported pres-
ence of pain reflected by the PA-score of 12.7% (Table 6).
The site of the pain in our cohort was not otherwise spe-
cified exept recording of dysuria. No gastrointestinal
pain was documented in the patients health records and
was not recalled at the final assessment. Other disease
processes and comorbidities associated with ageing, such
as musculo-skelettal disease also contribute to the gen-
eral measurement of life quality. In our cohort pain was
predominantly caused by degenerative musculo-skelettal
diseases.
The fact that 62.8% of the patients were under antihor-
monal therapy mean 3.2 years after adjuvant radiotherapy
indicates that the majority of patients had progressive dis-
ease despite an intensive local ablative concept. However
recent data showed that a significant proportion of pa-
tients may profit by having long term disease control or
delayed need of antihormonal therapy [13-16]. Further
studies are needed to evaluate which subgroup of patients
are likely to profit from this approach but this issue is be-
yond the scope of this study.
Our study has some limitations. First it is a retrospective
study and some symptoms may have not been docu-
mented in the patients records before, during ART and at
first follow up visit. However all patients received a weekly
consultation during ART which is a standard procedure in
the department of Radiation Oncology and it is not likely
that significant side effects have not been recorded. To
overcome this drawback all patients that followed the invi-
tation for physical consultation were asked if they recall
any side effects before, during and after ART. So if they
stated a symptom that was not recorded in the original
reports this recalled side effect was put to our statistics.
Second it is a single center study of an experimental ap-
proach. Although valid guidelines for pelvic radiother-
apy have been given and served as reference in the
radiotherapy planning process [20,21] salvage lymph
node dissection is not a standard procedure and num-
ber of removed lymph nodes as well as postoperative
morbidity depends on the experience of the surgery/ur-
ology department and the skills of the surgeon. There-
fore our observed low toxicities despite prior lymph
node dissection and second salvage lymph node dissec-
tion may be also the result of thorough experience with
this procedure.
Conclusion
Data of the present study indicate that extended salvage
lymph node dissection followed by adjuvant radiotherapy
Jilg et al. Radiation Oncology 2014, 9:178 Page 13 of 14
http://www.ro-journal.com/content/9/1/178is associated with low risk of only mild lymphedema even
after previous lymph node dissection in the primary
situation. Furthermore the characteristic of spectrum of
therapy-associated side effects was mild before, during
and after adjuvant radiotherapy and this combined ap-
proach may be regarded as a safe therapy. The spectrum
of adverse events mean 3.2 years after end of ART was al-
most equal to those before start of ART. Choline PET-CT
directed LND with adjuvant ART my serve as valid salvage
concept with good clinical response and low side effects.
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